ScripProtagonist Therapeutics may be far behind several other companies developing next-generation obesity drugs, but the company thinks it can narrow the gap by focusing on the oral market. The company an
ScripNektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with ato
ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C
Pink SheetBiotechnology Innovation Organization CEO John Crowley is feeling more optimistic about the state of the US Food and Drug Administration because the uncertainty of the early days of the Trump Administ